8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 12, 2026·SEC
Elanco Animal Health Incorporated(ELAN)Earnings, Financials & Key Ratios
ELAN•NYSE
$26.16
$13.06B mkt cap·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutElanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.Show more
- Revenue$4.71B+6.2%
- EBITDA$932M+2.1%
- Net Income-$232M-168.6%
- EPS (Diluted)-0.47-169.1%
- Gross Margin43.48%+1.1%
- EBITDA Margin19.77%-3.9%
- Operating Margin5.34%-5.5%
- Net Margin-4.92%-164.6%
- ROE-3.67%-166.9%
- ROIC1.89%+8.6%
- Debt/Equity0.61-13.4%
- Interest Coverage-0.02-100.7%
ELAN Key Insights
Elanco Animal Health Incorporated (ELAN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.2%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ELAN Price & Volume
Elanco Animal Health Incorporated (ELAN) stock price & volume — 10-year historical chart
Loading chart...
ELAN Growth Metrics
Elanco Animal Health Incorporated (ELAN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years7.57%
3 Years2.25%
TTM10.53%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-164.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-165.58%
Return on Capital
10 Years2.47%
5 Years2.27%
3 Years2.22%
Last Year2.19%
ELAN Recent Earnings
Elanco Animal Health Incorporated (ELAN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 6, 2026EPS
$0.40
Est $0.34
+17.6%
Revenue
$1.4B
Est $1.3B
+7.4%
Q1 2026
Feb 24, 2026EPS
$0.13
Est $0.11
+18.2%
Revenue
$1.1B
Est $1.1B
+4.7%
Q4 2025
Nov 5, 2025EPS
$0.19
Est $0.13
+46.2%
Revenue
$1.1B
Est $1.1B
+4.1%
Q3 2025
Aug 7, 2025EPS
$0.26
Est $0.20
+30.0%
Revenue
$1.2B
Est $1.1B
+13.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.40vs $0.34+17.6% | $1.4Bvs $1.3B+7.4% |
| Q1 2026 | Feb 24, 2026 | $0.13vs $0.11+18.2% | $1.1Bvs $1.1B+4.7% |
| Q4 2025 | Nov 5, 2025 | $0.19vs $0.13+46.2% | $1.1Bvs $1.1B+4.1% |
| Q3 2025 | Aug 7, 2025 | $0.26vs $0.20+30.0% | $1.2Bvs $1.1B+13.9% |
Based on last 12 quarters of dataView full earnings history →
ELAN Peer Comparison
Elanco Animal Health Incorporated (ELAN) competitors in Animal health pharmaceuticals and vaccines — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZTS | 46.95B | 111.22 | 18.48 | 2.28% | 28.23% | 58.23% | 2.85 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 PETS | 48.55M | 2.31 | -7.70 | -17.19% | -28.22% | -127.77% | 0.01 | |
 CHWY | 10.19B | 24.59 | 27.02 | 6.4% | 1.22% | 38.76% | 1.92 | |
 ANIP | 1.78B | 84.06 | 25.32 | 43.78% | 8.87% | 14.49% | 0.60 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare ELAN vs Peers
Elanco Animal Health Incorporated (ELAN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELAN Income Statement
Elanco Animal Health Incorporated (ELAN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.89B | 3.07B | 3.07B | 3.27B | 4.76B | 4.41B | 4.42B | 4.44B | 4.71B | 4.89B |
| Revenue Growth % | -0.84% | 6.15% | 0.14% | 6.59% | 45.54% | -7.41% | 0.14% | 0.5% | 6.22% | 10.53% |
| Cost of Goods Sold | 1.72B | 1.77B | 1.67B | 2.03B | 2.69B | 2.44B | 2.48B | 2.53B | 2.67B | 2.47B |
| COGS % of Revenue | 59.37% | 57.75% | 54.4% | 61.91% | 56.42% | 55.34% | 56.12% | 56.99% | 56.52% | - |
| Gross Profit | 1.17B▲ 0% | 1.3B▲ 10.4% | 1.4B▲ 8.1% | 1.25B▼ 11.0% | 2.08B▲ 66.5% | 1.97B▼ 5.1% | 1.94B▼ 1.6% | 1.91B▼ 1.5% | 2.05B▲ 7.4% | 2.42B▲ 0% |
| Gross Margin % | 40.63% | 42.25% | 45.6% | 38.09% | 43.58% | 44.66% | 43.88% | 43.01% | 43.48% | 49.44% |
| Gross Profit Growth % | -11.99% | 10.37% | 8.08% | -10.96% | 66.51% | -5.11% | -1.62% | -1.5% | 7.39% | - |
| Operating Expenses | 1.03B | 981.8M | 1.03B | 1.32B | 1.77B | 1.59B | 1.61B | 1.66B | 1.8B | 1.98B |
| OpEx % of Revenue | 35.7% | 32.01% | 33.55% | 40.44% | 37.2% | 35.96% | 36.5% | 37.35% | 38.13% | - |
| Selling, General & Admin | 779.8M | 735.2M | 760.2M | 996.6M | 1.4B | 1.26B | 1.28B | 1.31B | 1.43B | 1.47B |
| SG&A % of Revenue | 26.99% | 23.97% | 24.75% | 30.45% | 29.45% | 28.68% | 29.09% | 29.6% | 30.33% | - |
| Research & Development | 251.7M | 246.6M | 270.1M | 327M | 369M | 321M | 327M | 344M | 368M | 371M |
| R&D % of Revenue | 8.71% | 8.04% | 8.8% | 9.99% | 7.75% | 7.28% | 7.4% | 7.75% | 7.8% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Operating Income | 142.4M▲ 0% | 313.8M▲ 120.4% | 370M▲ 17.9% | -76.8M▼ 120.8% | 304M▲ 495.8% | 384M▲ 26.3% | 326M▼ 15.1% | 251M▼ 23.0% | 252M▲ 0.4% | 438M▲ 0% |
| Operating Margin % | 4.93% | 10.23% | 12.05% | -2.35% | 6.38% | 8.71% | 7.38% | 5.65% | 5.34% | 8.95% |
| Operating Income Growth % | -49.72% | 120.37% | 17.91% | -120.76% | 495.83% | 26.32% | -15.1% | -23.01% | 0.4% | - |
| EBITDA | 460.8M | 609.8M | 684.5M | 440.1M | 1.02B | 1.07B | 1.02B | 913M | 932M | 957M |
| EBITDA Margin % | 15.95% | 19.88% | 22.29% | 13.45% | 21.41% | 24.17% | 23.09% | 20.57% | 19.77% | 19.56% |
| EBITDA Growth % | -14.29% | 32.34% | 12.25% | -35.7% | 131.77% | 4.51% | -4.32% | -10.49% | 2.08% | 6.81% |
| D&A (Non-Cash Add-back) | 318.4M | 296M | 314.5M | 516.9M | 716M | 682M | 694M | 662M | 680M | 519M |
| EBIT | -232.6M | 143.7M | 157.1M | -516M | -307M | 184M | -918M | 827M | -4M | -71M |
| Net Interest Income | 0 | -29.6M | -78.9M | -156M | -264M | -256M | -277M | -339M | -175M | -191M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45M | 22M |
| Interest Expense | 0 | 29.6M | 78.9M | 156M | 264M | 256M | 277M | 339M | 220M | 270M |
| Other Income/Expense | -375M | -199.7M | -291.8M | -595.2M | -875M | -456M | -1.52B | 237M | -476M | -635M |
| Pretax Income | -232.6M▲ 0% | 114.1M▲ 149.1% | 78.2M▼ 31.5% | -672M▼ 959.3% | -571M▲ 15.0% | -72M▲ 87.4% | -1.2B▼ 1559.7% | 488M▲ 140.8% | -224M▼ 145.9% | -197M▲ 0% |
| Pretax Margin % | -8.05% | 3.72% | 2.55% | -20.53% | -11.99% | -1.63% | -27.05% | 10.99% | -4.75% | -4.03% |
| Income Tax | 78.1M | 27.6M | 10.3M | -111.9M | -88M | 6M | 36M | 150M | 8M | 45M |
| Effective Tax Rate % | -33.58% | 24.19% | 13.17% | 16.65% | 15.41% | -8.33% | -3.01% | 30.74% | -3.57% | -22.84% |
| Net Income | -310.7M▲ 0% | 86.5M▲ 127.8% | 67.9M▼ 21.5% | -560.1M▼ 924.9% | -483M▲ 13.8% | -78M▲ 83.9% | -1.23B▼ 1478.2% | 338M▲ 127.5% | -232M▼ 168.6% | -242M▲ 0% |
| Net Margin % | -10.75% | 2.82% | 2.21% | -17.11% | -10.14% | -1.77% | -27.87% | 7.61% | -4.92% | -4.95% |
| Net Income Growth % | -548.64% | 127.84% | -21.5% | -924.89% | 13.77% | 83.85% | -1478.21% | 127.46% | -168.64% | -164.88% |
| Net Income (Continuing) | -310.7M | 86.5M | 67.9M | -560.1M | -483M | -78M | -1.23B | 338M | -232M | -242M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.87▲ 0% | 0.28▲ 132.2% | 0.18▼ 35.7% | -1.27▼ 805.6% | -0.97▲ 23.6% | -0.15▲ 84.5% | -2.50▼ 1566.7% | 0.68▲ 127.2% | -0.47▼ 169.1% | -0.48▲ 0% |
| EPS Growth % | -569.23% | 132.18% | -35.71% | -805.56% | 23.62% | 84.54% | -1566.67% | 127.2% | -169.12% | -165.58% |
| EPS (Basic) | -0.87 | 0.28 | 0.18 | -1.27 | -0.97 | -0.15 | -2.50 | 0.68 | -0.47 | - |
| Diluted Shares Outstanding | 356.2M | 313.7M | 370.3M | 441.4M | 487.2M | 488.3M | 492.3M | 497.3M | 496.4M | 506M |
| Basic Shares Outstanding | 356.2M | 313.7M | 369M | 441.4M | 487.2M | 488.3M | 492.3M | 494M | 496.4M | 497.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ELAN Balance Sheet
Elanco Animal Health Incorporated (ELAN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.12B | 2.5B | 2.37B | 3.42B | 3.27B | 3.28B | 3.41B | 3.21B | 3.46B | 3.58B |
| Cash & Short-Term Investments | 323.4M | 474.8M | 334M | 495M | 638M | 345M | 352M | 468M | 545M | 428M |
| Cash Only | 323.4M | 474.8M | 334M | 495M | 638M | 345M | 352M | 468M | 545M | 428M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 601.9M | 709.4M | 889.9M | 1.08B | 1.03B | 1B | 1.01B | 886M | 940M | 1.15B |
| Days Sales Outstanding | 76.04 | 84.43 | 105.77 | 120.09 | 78.76 | 82.91 | 83.46 | 72.85 | 72.77 | 77.8 |
| Inventory | 1.06B | 1B | 1.05B | 1.58B | 1.37B | 1.54B | 1.74B | 1.57B | 1.74B | 1.72B |
| Days Inventory Outstanding | 226.07 | 206.92 | 229.55 | 284.22 | 186.17 | 229.98 | 255.46 | 227.08 | 237.9 | 251.99 |
| Other Current Assets | 0 | 202.7M | 11.1M | 11M | 0 | 394M | 310M | 287M | 236M | 285M |
| Total Non-Current Assets | 6.82B | 6.45B | 6.61B | 14.28B | 13.2B | 12.21B | 10.96B | 9.4B | 9.9B | 9.64B |
| Property, Plant & Equipment | 920.3M | 922.4M | 955.3M | 1.32B | 1.05B | 999M | 1.03B | 993M | 1.41B | 1.4B |
| Fixed Asset Turnover | 3.14x | 3.32x | 3.21x | 2.49x | 4.52x | 4.42x | 4.31x | 4.47x | 3.35x | 3.52x |
| Goodwill | 2.97B | 2.96B | 2.99B | 6.22B | 6.17B | 5.99B | 5.09B | 4.41B | 4.78B | 4.72B |
| Intangible Assets | 2.67B | 2.45B | 2.48B | 6.39B | 5.59B | 4.84B | 4.49B | 3.68B | 3.41B | 3.23B |
| Long-Term Investments | 12.3M | 15.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14M |
| Other Non-Current Assets | 242M | 103.1M | 185M | 348M | 390M | 378M | 341M | 311M | 304M | 1.2B |
| Total Assets | 8.94B▲ 0% | 8.96B▲ 0.2% | 8.99B▲ 0.3% | 17.69B▲ 96.9% | 16.48B▼ 6.9% | 15.49B▼ 6.0% | 14.36B▼ 7.3% | 12.61B▼ 12.2% | 13.36B▲ 5.9% | 13.22B▲ 0% |
| Asset Turnover | 0.32x | 0.34x | 0.34x | 0.19x | 0.29x | 0.28x | 0.31x | 0.35x | 0.35x | 0.36x |
| Asset Growth % | 10.38% | 0.18% | 0.32% | 96.9% | -6.87% | -5.99% | -7.29% | -12.17% | 5.9% | 9.93% |
| Total Current Liabilities | 632.6M | 970.7M | 818.5M | 2.08B | 1.65B | 1.7B | 1.24B | 1.31B | 1.6B | 1.66B |
| Accounts Payable | 203.8M | 205.2M | 222.6M | 501M | 416M | 390M | 270M | 296M | 368M | 372M |
| Days Payables Outstanding | 43.37 | 42.29 | 48.63 | 90.24 | 56.49 | 58.32 | 39.75 | 42.7 | 50.4 | 53.85 |
| Short-Term Debt | 0 | 29M | 24.5M | 555M | 294M | 388M | 38M | 44M | 74M | 73M |
| Deferred Revenue (Current) | 0 | 367.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 169.2M | 736.5M | 555M | 1.02B | 937M | 924M | 933M | 975M | 1.16B | 1.59B |
| Current Ratio | 3.36x | 2.58x | 2.90x | 1.65x | 1.99x | 1.93x | 2.75x | 2.44x | 2.17x | 2.17x |
| Quick Ratio | 1.68x | 1.55x | 1.62x | 0.89x | 1.16x | 1.02x | 1.35x | 1.25x | 1.08x | 1.08x |
| Cash Conversion Cycle | 258.75 | 249.06 | 286.68 | 314.08 | 208.44 | 254.57 | 299.16 | 257.23 | 260.27 | 275.94 |
| Total Non-Current Liabilities | 516.9M | 2.79B | 2.62B | 7.14B | 7.32B | 6.5B | 6.9B | 5.2B | 5.21B | 5.06B |
| Long-Term Debt | 0 | 2.44B | 2.33B | 5.57B | 6.03B | 5.45B | 5.74B | 4.28B | 3.94B | 3.92B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 251.9M | 114.6M | 100.8M | 900M | 765M | 662M | 567M | 449M | 0 | 496M |
| Other Non-Current Liabilities | 265M | 230.6M | 189.1M | 668M | 533M | 390M | 595M | 477M | 1.27B | 4.73B |
| Total Liabilities | 1.15B | 3.76B | 3.44B | 9.22B | 8.97B | 8.2B | 8.14B | 6.52B | 6.81B | 6.72B |
| Total Debt | 0 | 2.47B | 2.35B | 6.13B | 6.32B | 5.84B | 5.77B | 4.32B | 4.02B | 3.99B |
| Net Debt | -323.4M | 2B | 2.02B | 5.63B | 5.68B | 5.49B | 5.42B | 3.85B | 3.47B | 3.56B |
| Debt / Equity | - | 0.48x | 0.42x | 0.72x | 0.84x | 0.80x | 0.93x | 0.71x | 0.61x | 0.61x |
| Debt / EBITDA | - | 4.05x | 3.44x | 13.92x | 6.20x | 5.47x | 5.66x | 4.73x | 4.31x | 4.17x |
| Net Debt / EBITDA | -0.70x | 3.28x | 2.95x | 12.80x | 5.57x | 5.15x | 5.32x | 4.22x | 3.73x | 3.73x |
| Interest Coverage | - | 4.85x | 1.99x | -3.31x | -1.16x | 0.72x | -3.31x | 2.44x | -0.02x | -0.26x |
| Total Equity | 7.79B▲ 0% | 5.2B▼ 33.3% | 5.55B▲ 6.7% | 8.48B▲ 52.8% | 7.51B▼ 11.4% | 7.29B▼ 2.9% | 6.22B▼ 14.6% | 6.1B▼ 2.0% | 6.55B▲ 7.4% | 6.5B▲ 0% |
| Equity Growth % | 10.86% | -33.29% | 6.72% | 52.81% | -11.42% | -2.92% | -14.62% | -2.04% | 7.4% | 27.2% |
| Book Value per Share | 21.87 | 16.57 | 14.98 | 19.20 | 15.41 | 14.93 | 12.64 | 12.26 | 13.19 | 12.85 |
| Total Shareholders' Equity | 7.79B | 5.2B | 5.55B | 8.48B | 7.51B | 7.29B | 6.22B | 6.1B | 6.55B | 6.5B |
| Common Stock | 8.05B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 0 | 16.4M | 84.3M | -477M | -979M | -1.06B | -2.29B | -1.95B | -2.18B | -2.13B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -256.6M | -222.2M | -173.7M | 303M | -209M | -392M | -266M | -771M | -141M | -233M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELAN Cash Flow Statement
Elanco Animal Health Incorporated (ELAN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 173.8M | 487.3M | 224.1M | -41M | 483M | 452M | 271M | 541M | 560M | 560M |
| Operating CF Margin % | 6.02% | 15.89% | 7.3% | -1.25% | 10.14% | 10.25% | 6.14% | 12.19% | 11.88% | - |
| Operating CF Growth % | 11.48% | 180.38% | -54.01% | -118.3% | 1278.05% | -6.42% | -40.04% | 99.63% | 3.51% | 439.7% |
| Net Income | -310.7M | 86.5M | 67.9M | -574M | -472M | -78M | -1.23B | 338M | -232M | -242M |
| Depreciation & Amortization | 318.4M | 296M | 314.5M | 517M | 716M | 682M | 694M | 662M | 680M | 691M |
| Stock-Based Compensation | 25M | 26M | 49.4M | 47M | 66M | 59M | 46M | 55M | 68M | 74M |
| Deferred Taxes | -13.4M | -60.7M | 100K | -114M | -154M | -57M | -80M | -112M | -134M | -134M |
| Other Non-Cash Items | 101M | 168.7M | 19.9M | -86M | 414M | 308M | 1.14B | -551M | 79M | 104M |
| Working Capital Changes | 53.5M | -29.2M | -227.7M | 169M | -87M | -462M | -300M | 149M | 99M | 40M |
| Change in Receivables | 48.4M | -122M | -172.4M | 24M | -3M | 14M | -40M | 12M | -12M | 0 |
| Change in Inventory | -39M | -20.1M | -33.1M | -95M | 27M | -269M | -160M | 44M | -57M | 0 |
| Change in Payables | -8.4M | 116.1M | -29.2M | 362M | -120M | -98M | -94M | 82M | 147M | 0 |
| Cash from Investing | -964.6M | -127M | -234.8M | -4.78B | -530M | -179M | -169M | 1.16B | -279M | -281M |
| Capital Expenditures | -98.6M | -134.5M | -197.4M | -310.9M | -197M | -184M | -140M | -147M | -276M | -262M |
| CapEx % of Revenue | 3.41% | 4.39% | 6.43% | 9.5% | 4.14% | 4.17% | 3.17% | 3.31% | 5.85% | - |
| Acquisitions | -882.1M | 9.4M | -32.8M | -4.57B | -342M | 13M | -19M | 1.32B | 0 | -7M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 16.1M | -1.9M | -4.6M | 169.2M | 9M | -8M | -10M | -14M | -3M | -12M |
| Cash from Financing | 847.5M | -35.2M | -304.8M | 4.95B | 210M | -549M | -83M | -1.49B | -275M | -392M |
| Debt Issued (Net) | 0 | 2.49B | -121M | 3.85B | 177M | -517M | -77M | -1.48B | -563M | -72M |
| Equity Issued (Net) | 0 | 1.66B | 0 | 1.22B | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 847.5M | -4.19B | -183.8M | -118.1M | 33M | -32M | -6M | -17M | 288M | -320M |
| Net Change in Cash | 64.6M▲ 0% | 354.1M▲ 448.1% | -332.4M▼ 193.9% | 160.3M▲ 148.2% | 132M▼ 17.7% | -293M▼ 322.0% | 7M▲ 102.4% | 116M▲ 1557.1% | 77M▼ 33.6% | -59M▲ 0% |
| Free Cash Flow | 75.2M▲ 0% | 352.8M▲ 369.1% | 26.7M▼ 92.4% | -351.9M▼ 1418.0% | 286M▲ 181.3% | 268M▼ 6.3% | 117M▼ 56.3% | 394M▲ 236.8% | 284M▼ 27.9% | 315M▲ 0% |
| FCF Margin % | 2.6% | 11.5% | 0.87% | -10.75% | 6% | 6.08% | 2.65% | 8.88% | 6.02% | 6.44% |
| FCF Growth % | 64.91% | 369.15% | -92.43% | -1417.98% | 181.27% | -6.29% | -56.34% | 236.75% | -27.92% | -7.62% |
| FCF per Share | 0.21 | 1.12 | 0.07 | -0.80 | 0.59 | 0.55 | 0.24 | 0.79 | 0.57 | 0.57 |
| FCF Conversion (FCF/Net Income) | -0.56x | 5.63x | 3.30x | 0.07x | -1.00x | -5.79x | -0.22x | 1.60x | -2.41x | -1.30x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 379M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELAN Key Ratios
Elanco Animal Health Incorporated (ELAN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -4.19% | 1.33% | 1.26% | -7.99% | -6.04% | -1.05% | -18.22% | 5.49% | -3.67% | -3.64% |
| Return on Invested Capital (ROIC) | 1.5% | 3.21% | 3.76% | -0.53% | 1.67% | 2.22% | 2% | 1.74% | 1.89% | 1.89% |
| Gross Margin | 40.63% | 42.25% | 45.6% | 38.09% | 43.58% | 44.66% | 43.88% | 43.01% | 43.48% | 49.44% |
| Net Margin | -10.75% | 2.82% | 2.21% | -17.11% | -10.14% | -1.77% | -27.87% | 7.61% | -4.92% | -4.95% |
| Debt / Equity | - | 0.48x | 0.42x | 0.72x | 0.84x | 0.80x | 0.93x | 0.71x | 0.61x | 0.61x |
| Interest Coverage | - | 4.85x | 1.99x | -3.31x | -1.16x | 0.72x | -3.31x | 2.44x | -0.02x | -0.26x |
| FCF Conversion | -0.56x | 5.63x | 3.30x | 0.07x | -1.00x | -5.79x | -0.22x | 1.60x | -2.41x | -1.30x |
| Revenue Growth | -0.84% | 6.15% | 0.14% | 6.59% | 45.54% | -7.41% | 0.14% | 0.5% | 6.22% | 10.53% |
ELAN SEC Filings & Documents
Elanco Animal Health Incorporated (ELAN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELAN Frequently Asked Questions
Elanco Animal Health Incorporated (ELAN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Elanco Animal Health Incorporated (ELAN) reported $4.89B in revenue for fiscal year 2025. This represents a 68% increase from $2.91B in 2016.
Elanco Animal Health Incorporated (ELAN) grew revenue by 6.2% over the past year. This is steady growth.
Elanco Animal Health Incorporated (ELAN) reported a net loss of $242.0M for fiscal year 2025.
Dividend & Returns
Elanco Animal Health Incorporated (ELAN) has a return on equity (ROE) of -3.7%. Negative ROE indicates the company is unprofitable.
Elanco Animal Health Incorporated (ELAN) generated $315.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ELAN
Elanco Animal Health Incorporated (ELAN) financial analysis — history, returns, DCA and operating performance tools
Full ELAN Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates